Hormone therapy for the management of menopausal symptoms: Pharmacotherapy update

Journal of Pharmacy Practice

Volumn 23, Issue 6, 2010, Pages 540-547

  Brock Woodis, C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

hormone therapy; menopause; pharmacotherapy; vasomotor

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTRADIOL ACETATE; ESTROGEN; ETHINYL ESTRADIOL PLUS NORETHINDRONE ACETATE; FEMHRT; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HEART INFARCTION; HIP FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MASTALGIA; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PRACTICE GUIDELINE; SIDE EFFECT; SPOTTING; STROKE; TREATMENT CONTRAINDICATION; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 78650195612     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009360061     Document Type: Article

References (35)

1. Hill K. The demography of menopause. Maturitas. 1996 ; 23 (2). 113-127.
2. Nelson HD Menopause. Lancet. 2008 ; 371 (9614). 760-770.
3. Gracia CR, Sammel MD, Freeman EW, et al. Defining menopause status: creation of a new definition to identify the early stages of the menopausal transition. Menopause. 2005 ; 12 (2). 128-135.
4. Col NF, Fairfield KM, Ewan-White C., et al. In the clinic. Menopause. Ann Intern Med. 2009 ; 150 (7). ITC4-1-15.
5. Kase NG Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement. Gend Med. 2009 ; 6 (suppl 1). 37-59.
6. Santoro N. The menopausal transition. Am J Med. 2005 ; 118 (suppl 12B). 8S - 13S.
7. Ringa V. Menopause and treatments. Qual Life Res. 2000 ; 9 (suppl 6). 695-707.
8. Soules MR, Sherman S., Parrott E., et al. Stages of reproductive aging workshop (STRAW). J Womens Health Gend Based Med. 2001 ; 10 (9). 843-848.
9. Alexander IM, Moore A. Treating vasomotor symptoms of menopause: the nurse practitioner's perspective. J Am Acad Nurse Pract. 2007 ; 19 (3). 152-163.
10. Shen W., Stearns V. Treatment strategies for hot flushes. Expert Opin Pharmacother. 2009 ; 10 (7). 1133-1144.
11. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril. 2008 ; 90 (5 suppl). S88 - S102.
12. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause. 2007 ; 14 (2). 168-182.
13. Hickey M., Davis SR, Sturdee DW Treatment of menopausal symptoms: what shall we do now ? Lancet. 2005 ; 366 (9483). 409-421.
14. Gas M. Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy. Cleve Clin J Med. 2008 ; 75 (suppl 4). S13 - S16.
15. Studd J. Second thoughts on the Women's Health Initiative study: the effect of age on the safety of HRT. Climacteric. 2004 ; 7 (4). 412-414.
16. Greendale GA, Reboussin BA, Hogan P., et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestins trial. Obstet Gynecol. 1998 ; 92 (6). 982-988.
17. AACE Menopause Guidelines Revision Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Menopause. Endocr Pract. 2006 ; 12 (3). 317-337.
18. Schmidt JW, Wollner D., Curcio J., et al. Hormone replacement therapy in menopausal women: past problems and future possibilities. Gynecol Endocrinol. 2006 ; 22 (10). 564-577.
19. The Women's Health Initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004 ; 291 (14). 1701-1712.
20. Lam POM, Chung TKH, Haines C. Where are we with postmenopausal hormone therapy in 2005 ? Gynecol Endocrinol. 2005 ; 21 (5). 248-256.
21. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998 ; 280 (7). 605-613.
22. Tan O., Harman SM, Naftolin F. What can we learn from design faults in the Women's Health Initiative randomized clinical trial? Bull NYU Hosp Jt Dis. 2009 ; 67 (2). 226-229.
23. Rossouw JE, Anderson GL, Prentice RL, et al, and Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002 ; 288 (3). 321-333.
24. Hulley SB, Grady S. The WHI estrogen-alone trial-do things look any better? JAMA. 2204 ; 291 (14). 1769-1771.
25. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007 ; 297 (13). 1465-1477.
26. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010 ; 17 (2). 242-255.
27. Palacios S., Foidart JM, Genazzani AR Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 2006 ; 55 (4). 297-307.
28. Shurmann R., Holler T., Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric. 2004 ; 7 (2). 189-196.
29. Lee BS, Kang BM, Yoon BK, et al. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007 ; 57 (4). 361-369.
30. Archer DF, Thorneycroft IH, Foegh M., et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005 ; 12 (6). 716-727.
31. Angeliq (drospirenone/estradiol) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2008.
32. Suffoletto J., Hess R. Tapering versus cold turkey: symptoms versus successful discontinuation of menospausal hormone therapy. Menopause. 2009 ; 16 (3). 436-437.
33. Grady D., Sawaya GF Discontinuation of postmenopausal hormone therapy. Am J Med. 2005 ; 118 (suppl 12B). 163S - 165S.
34. Haskell S., Bean-Mayberry B., Gordon K. Discontinuing postmenopausal hormone therapy in an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause. 2009; 16 (3). 494-499.
35. Hormone products for postmenopausal use in the United States and Canada. Compiled by the North American Menopause Society, 2009.